Cambridge Major Increases API Capacity
The expansion comes only three years after commissioning the new state-of-the-art facility, further validating CML’s business model of focused investment in US-based assets.
“We are very pleased to report that our faith in the “invest in the West” policy initiated a few years ago continues to bear fruit,” commented Brian Scanlan, President & CEO. “CML is very well positioned to support both increasing demand for our commercial products as well as our healthy pipeline of API’s in later phases of clinical development. By making these new investments, we show our commitment to support our loyal client base at the most critical point, when quality and timely delivery are imperative.”
The expansion will include significant additional reactor capacity as well as isolation equipment. Alongside capacity additions, CML has made additional investments in engineering controls to ensure the sustainability of the business. “Our Environmental, Health, and Safety commitments underpin all operations, and we have invested further containment capabilities with engineering controls across production trains. Additional containment capabilities will also be introduced into our European facility later this year,” added Scanlan.
Following the commissioning of the large scale API facility in 2009, CML has more recently invested in other supporting areas of the business, such as Solid State services and an expanded analytical offering. “CML is committed to becoming the long-term partner of choice for complex API development projects”, commented Roger McDonald, European Business Development Director. “Even clients in Phase I have the comfort of knowing they can potentially stay with us through product launch – plan for success!”